Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

<p>Background: Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments have made remission or near-remission of most symptoms a potentially achievable goal for many patients. We sought to evaluate whether achieving minimal disease activity (MDA) cri...

Descripció completa

Dades bibliogràfiques
Autors principals:	Coates, L, Orbai, A, Morita, A, Benichou, O, Kerr, L, Adams, D, Shuler, C, Birt, J, Helliwell, P
Format:	Journal article
Publicat:	BioMed Central 2018

Ítems similars

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
per: Laura C. Coates, et al.
Publicat: (2018-08-01)

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial
per: Orbai, AM, et al.
Publicat: (2021)

Current concepts and unmet needs in psoriatic arthritis
per: Mahmood, F, et al.
Publicat: (2017)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
per: Coates, L, et al.
Publicat: (2016)

Classification and outcome measures for psoriatic arthritis
per: Leung, Y, et al.
Publicat: (2018)

Assessing disease activity in psoriatic arthritis: a literature review
per: Tucker, L, et al.
Publicat: (2018)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
per: Yazji, SM, et al.
Publicat: (2025)

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phase 3 study
per: Orbai, A-M, et al.
Publicat: (2022)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
per: P.S. Helliwell
Publicat: (2011-09-01)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
per: Coates, L, et al.
Publicat: (2016)

Sustained very low disease activity and remission in psoriatic arthritis patients
per: Lubrano, E, et al.
Publicat: (2019)

Classification and Outcome Measures for Psoriatic Arthritis
per: Ying Ying Leung, et al.
Publicat: (2018-09-01)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
per: Coates, L, et al.
Publicat: (2019)

Psoriatic Arthritis: A Review
per: Farrouq Mahmood, et al.
Publicat: (2016-07-01)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
per: Coates, LC, et al.
Publicat: (2021)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
per: Coates, L, et al.
Publicat: (2022)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
per: Orbai, A-M, et al.
Publicat: (2019)

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
per: Peter Nash, et al.
Publicat: (2020-02-01)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
per: Kavanaugh, A, et al.
Publicat: (2024)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
per: Miller J, et al.
Publicat: (2021-12-01)

Comparing the patient reported physical function outcome measures in a real‐life international cohort of patients with psoriatic arthritis
per: Leung, YY, et al.
Publicat: (2021)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
per: Tillett, W, et al.
Publicat: (2017)

The road to personalised medicine in psoriatic arthritis
per: White, JPE, et al.
Publicat: (2021)

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
per: Coates, LC, et al.
Publicat: (2020)

What should be the primary target of "treat to target" in psoriatic arthritis?
per: Coates, LC, et al.
Publicat: (2018)

Search for predictors of achieving minimal disease activity during tofacitinib therapy in patients with psoriatic arthritis
per: L. D. Vorobyova, et al.
Publicat: (2023-12-01)

Psoriatic arthritis: prospects for the future
per: Hackett, S, et al.
Publicat: (2022)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
per: Weinstein, SM, et al.
Publicat: (2021)

The impact of psoriatic arthritis on quality of life: a systematic review
per: James, L, et al.
Publicat: (2024)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
per: L. C. Coates, et al.
Publicat: (2020-06-01)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
per: Ennio Lubrano, et al.
Publicat: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
per: Silvia Scriffignano, et al.
Publicat: (2023-09-01)

Methotrexate in psoriasis and psoriatic arthritis
per: Coates, L, et al.
Publicat: (2020)

Considerations for the definition of remission criteria in psoriatic arthritis
per: Mease, P, et al.
Publicat: (2017)

Identification of psoriatic arthritis in patients with psoriasis
per: Coates, LC, et al.
Publicat: (2023)

Psoriatic arthritis: prospects for the future
per: Simon Hackett, et al.
Publicat: (2022-03-01)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
per: Coates, L, et al.
Publicat: (2019)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
per: Ye, W, et al.
Publicat: (2021)